Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

1d ago, source:

Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Learn ...

SPRO Spero Therapeutics, Inc.

7d ago, source: Seeking Alpha

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections ...

Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates

1mon ago, source: Zacks.com on MSN

Spero Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $73.52 million for the quarter ended December 2023, surpassing the Zacks ...

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

1mon ago, source: Yahoo Finance

Most readers would already be aware that Spero Therapeutics' (NASDAQ:SPRO) stock increased significantly by 35% over the past three months. Since the market usually pay for a company’s long-term ...

The Volatility of Spero Therapeutics Inc’s (SPRO) Stock: A 0.91% Ratio for the Week

12d ago, source: newsheater

The stock of Spero Therapeutics Inc (SPRO) has gone up by 0.91% for the week, with a 0.30% rise in the past month and a 14.04% rise in the past quarter. The volatility ratio for the week is 4.69%, and ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript

1mon ago, source: Insider Monkey

Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1. SPRO isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

1mon ago, source: Finanznachrichten

March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare ...

Spero Therapeutics Inc SPRO

10d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spero Therapeutics Inc.

6d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Spero Therapeutics Inc SPRO

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...